Vivos Therapeutics, Inc. (VVOS)
| Market Cap | 13.77M |
| Revenue (ttm) | 14.58M |
| Net Income (ttm) | -12.57M |
| Shares Out | 4.77M |
| EPS (ttm) | -3.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,545 |
| Open | 2.860 |
| Previous Close | 2.830 |
| Day's Range | 2.770 - 2.970 |
| 52-Week Range | 1.910 - 48.790 |
| Beta | 7.68 |
| Analysts | Strong Buy |
| Price Target | 6.30 (+117.99%) |
| Earnings Date | Nov 14, 2024 |
About VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and s... [Read more]
Financial Performance
In 2023, Vivos Therapeutics's revenue was $13.80 million, a decrease of -13.87% compared to the previous year's $16.02 million. Losses were -$13.58 million, -43.04% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for VVOS stock is "Strong Buy." The 12-month stock price forecast is $6.3, which is an increase of 117.99% from the latest price.
News
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants ...
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payer...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model
Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants John Lee - Vivos' Executive Vice President of Marketing Kirk Huntsman - Chairma...
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives...
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances 8 Out of 10 Newly Diagn...
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos' Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit
Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2024 Results Conference Call May 14, 2024 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman & Chief Executiv...
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development a...
Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea ...
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos' Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos De...
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA
New Dentist Inquiries Jumped 600% and Signed Dentist Enrollment Contracts up 38% Sequentially Over Q3 CARE Oral Medical Device Unit Orders Increased 26% Following FDA Clearance LITTLETON, Colo., Jan. ...
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”
Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA Vivos unites influential women l...
Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance
Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea.
US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea
Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA).
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos With this unprec...
Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2023 Earnings Conference Call November 14, 2023 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman and Chief ...
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expe...
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for pat...